Ann: ANP Updates on US Regulatory Plans for ATL1102 in DMD, page-117

Upthefog I completely agree: management seemingly “didn’t get it right the first time”
Another thing I find really disappointing is the reply synapse received from ANP in the person of Mr Gennadi Koutchin, which by the way apparently is working for XEC Partners an accounting company, not for ANP so I am not sure how valid is his reply as in my view being the accountant is probably not too familiar with various Bio FDA regulation in fact (and this is laughable) instead of giving an explanation it refers to Morgan research note released yesterday.
This is another P.R. gem from the Diamond. He cannot even explain/clarify yesterday enigmatic announcement. Yes we are definitely in good hands with him at the helm
Let’s hope the board changes mentioned by Dr. C. Gittleson will come sooner than later.